• Neurophet partnered with RapidAI to integrate its neurodegenerative brain imaging solutions into the Rapid Enterprise Platform, expanding access to U.S. health systems.
• Initial distribution will target U.S. memory disorders centers prescribing Alzheimer's treatments Leqembi and Kisunla, using AQUA AD Plus for treatment safety monitoring.
• Planned platform expansion includes additional dementia imaging tools; the partnership also covers multiple sclerosis imaging analysis.
• RapidAI's existing customer network spans more than 2,500 hospitals across 100 countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurophet Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN86473) on November 02, 2026, and is solely responsible for the information contained therein.